Search Results - "CLINICAL CANCER RESEARCH"

Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial by Xu, Jianming, Shen, Jie, Gu, Shanzhi, Zhang, Yun, Wu, Lihua, Wu, Jian, Shao, Guoliang, Zhang, Yanqiao, Xu, Li, Yin, Tao, Liu, Jingfeng, Ren, Zhenggang, Xiong, Jianping, Mao, Xianhai, Zhang, Ling, Yang, Jiayin, Li, Lequn, Chen, Xiaoming, Wang, Zhiming, Gu, Kangsheng, Chen, Xi, Pan, Zhanyu, Ma, Kuansheng, Zhou, Xinmin, Yu, Zujiang, Li, Enxiao, Yin, Guowen, Zhang, Xiao, Wang, Shuni, Wang, Quanren

“…We assessed the efficacy and safety of camrelizumab [an anti-programmed death (PD-1) mAb] plus apatinib (a VEGFR-2 tyrosine kinase inhibitor) in patients with…”
Get full text

FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors by Marcus, Leigh, Lemery, Steven J, Keegan, Patricia, Pazdur, Richard

“…The FDA approved pembrolizumab on May 23, 2017, for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite…”
Get full text

Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis by Spring, Laura M, Fell, Geoffrey, Arfe, Andrea, Sharma, Chandni, Greenup, Rachel, Reynolds, Kerry L, Smith, Barbara L, Alexander, Brian, Moy, Beverly, Isakoff, Steven J, Parmigiani, Giovanni, Trippa, Lorenzo, Bardia, Aditya

“…While various studies have highlighted the prognostic significance of pathologic complete response (pCR) after neoadjuvant chemotherapy (NAT), the impact of…”
Get full text

Oxidative Phosphorylation as an Emerging Target in Cancer Therapy by Ashton, Thomas M, McKenna, W Gillies, Kunz-Schughart, Leoni A, Higgins, Geoff S

“…Cancer cells have upregulated glycolysis compared with normal cells, which has led many to the assumption that oxidative phosphorylation (OXPHOS) is…”
Get full text

Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes by Doroshow, Deborah B, Sanmamed, Miguel F, Hastings, Katherine, Politi, Katerina, Rimm, David L, Chen, Lieping, Melero, Ignacio, Schalper, Kurt A, Herbst, Roy S

“…Immune-checkpoint inhibitors (ICI), particularly inhibitors of the PD-1 axis, have altered the management of non-small cell lung cancer (NSCLC) over the last…”
Get full text

Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade by House, Imran G, Savas, Peter, Lai, Junyun, Chen, Amanda X Y, Oliver, Amanda J, Teo, Zhi L, Todd, Kirsten L, Henderson, Melissa A, Giuffrida, Lauren, Petley, Emma V, Sek, Kevin, Mardiana, Sherly, Gide, Tuba N, Quek, Camelia, Scolyer, Richard A, Long, Georgina V, Wilmott, James S, Loi, Sherene, Darcy, Phillip K, Beavis, Paul A

“…Response rates to immune checkpoint blockade (ICB; anti-PD-1/anti-CTLA-4) correlate with the extent of tumor immune infiltrate, but the mechanisms underlying…”
Get full text

The Advantage of FLASH Radiotherapy Confirmed in Mini-pig and Cat-cancer Patients by Vozenin, Marie-Catherine, De Fornel, Pauline, Petersson, Kristoffer, Favaudon, Vincent, Jaccard, Maud, Germond, Jean-François, Petit, Benoit, Burki, Marco, Ferrand, Gisèle, Patin, David, Bouchaab, Hanan, Ozsahin, Mahmut, Bochud, François, Bailat, Claude, Devauchelle, Patrick, Bourhis, Jean

“…Previous studies using FLASH radiotherapy (RT) in mice showed a marked increase of the differential effect between normal tissue and tumors. To stimulate…”
Get full text

Deep Learning Predicts Lung Cancer Treatment Response from Serial Medical Imaging by Xu, Yiwen, Hosny, Ahmed, Zeleznik, Roman, Parmar, Chintan, Coroller, Thibaud, Franco, Idalid, Mak, Raymond H, Aerts, Hugo J W L

“…Tumors are continuously evolving biological systems, and medical imaging is uniquely positioned to monitor changes throughout treatment. Although qualitatively…”
Get full text

WNT/β-catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers by Luke, Jason J, Bao, Riyue, Sweis, Randy F, Spranger, Stefani, Gajewski, Thomas F

“…The T-cell-inflamed phenotype correlates with efficacy of immune-checkpoint blockade, whereas non-T-cell-inflamed tumors infrequently benefit. Tumor-intrinsic…”
Get full text

Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non-small Cell Lung Cancer by Leighl, Natasha B, Page, Ray D, Raymond, Victoria M, Daniel, Davey B, Divers, Stephen G, Reckamp, Karen L, Villalona-Calero, Miguel A, Dix, Daniel, Odegaard, Justin I, Lanman, Richard B, Papadimitrakopoulou, Vassiliki A

“…Complete and timely tissue genotyping is challenging, leading to significant numbers of patients with newly diagnosed metastatic non-small cell lung cancer…”
Get full text

Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1 by Champiat, Stéphane, Dercle, Laurent, Ammari, Samy, Massard, Christophe, Hollebecque, Antoine, Postel-Vinay, Sophie, Chaput, Nathalie, Eggermont, Alexander, Marabelle, Aurélien, Soria, Jean-Charles, Ferté, Charles

“…While immune checkpoint inhibitors are disrupting the management of patients with cancer, anecdotal occurrences of rapid progression (i.e., hyperprogressive…”
Get full text

CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors by Majzner, Robbie G, Theruvath, Johanna L, Nellan, Anandani, Heitzeneder, Sabine, Cui, Yongzhi, Mount, Christopher W, Rietberg, Skyler P, Linde, Miles H, Xu, Peng, Rota, Christopher, Sotillo, Elena, Labanieh, Louai, Lee, Daniel W, Orentas, Rimas J, Dimitrov, Dimiter S, Zhu, Zhongyu, Croix, Brad St, Delaidelli, Alberto, Sekunova, Alla, Bonvini, Ezio, Mitra, Siddhartha S, Quezado, Martha M, Majeti, Ravindra, Monje, Michelle, Sorensen, Poul H B, Maris, John M, Mackall, Crystal L

“…Patients with relapsed pediatric solid tumors and CNS malignancies have few therapeutic options and frequently die of their disease. Chimeric antigen receptor…”
Get full text

Deep Learning-Based Multi-Omics Integration Robustly Predicts Survival in Liver Cancer by Chaudhary, Kumardeep, Poirion, Olivier B, Lu, Liangqun, Garmire, Lana X

“…Identifying robust survival subgroups of hepatocellular carcinoma (HCC) will significantly improve patient care. Currently, endeavor of integrating multi-omics…”
Get full text

The Role of Angiogenesis in Hepatocellular Carcinoma by Morse, Michael A, Sun, Weijing, Kim, Richard, He, Aiwu Ruth, Abada, Paolo B, Mynderse, Michelle, Finn, Richard S

“…Hepatocellular carcinoma (HCC) accounts for about 90% of all primary liver cancers and is the second leading cause of cancer-related deaths worldwide. The…”
Get full text

Tumor Mutational Burden as a Predictor of Immunotherapy Response: Is More Always Better? by Strickler, John H, Hanks, Brent A, Khasraw, Mustafa

“…Immune checkpoint inhibitors, including antibodies that block programmed cell death protein-1 (PD-1) and PD-L1, have transformed the management of many…”
Get full text

Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study by Abida, Wassim, Campbell, David, Patnaik, Akash, Shapiro, Jeremy D, Sautois, Brieuc, Vogelzang, Nicholas J, Voog, Eric G, Bryce, Alan H, McDermott, Ray, Ricci, Francesco, Rowe, Julie, Zhang, Jingsong, Piulats, Josep Maria, Fizazi, Karim, Merseburger, Axel S, Higano, Celestia S, Krieger, Laurence E, Ryan, Charles J, Feng, Felix Y, Simmons, Andrew D, Loehr, Andrea, Despain, Darrin, Dowson, Melanie, Green, Foad, Watkins, Simon P, Golsorkhi, Tony, Chowdhury, Simon

“…Genomic alterations in DNA damage repair (DDR) genes other than may confer synthetic lethality with PARP inhibition in metastatic castration-resistant prostate…”
Get full text

PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression by Jiao, Shiping, Xia, Weiya, Yamaguchi, Hirohito, Wei, Yongkun, Chen, Mei-Kuang, Hsu, Jung-Mao, Hsu, Jennifer L, Yu, Wen-Hsuan, Du, Yi, Lee, Heng-Huan, Li, Chia-Wei, Chou, Chao-Kai, Lim, Seung-Oe, Chang, Shih-Shin, Litton, Jennifer, Arun, Banu, Hortobagyi, Gabriel N, Hung, Mien-Chie

“…To explore whether a cross-talk exists between PARP inhibition and PD-L1/PD-1 immune checkpoint axis, and determine whether blockade of PD-L1/PD-1 potentiates…”
Get full text

Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate by Kato, Shumei, Goodman, Aaron, Walavalkar, Vighnesh, Barkauskas, Donald A, Sharabi, Andrew, Kurzrock, Razelle

“…Checkpoint inhibitors demonstrate salutary anticancer effects, including long-term remissions. PD-L1 expression/amplification, high mutational burden, and…”
Get full text

Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies by Harding, James J, Nandakumar, Subhiksha, Armenia, Joshua, Khalil, Danny N, Albano, Melanie, Ly, Michele, Shia, Jinru, Hechtman, Jaclyn F, Kundra, Ritika, El Dika, Imane, Do, Richard K, Sun, Yichao, Kingham, T Peter, D'Angelica, Michael I, Berger, Michael F, Hyman, David M, Jarnagin, William, Klimstra, David S, Janjigian, Yelena Y, Solit, David B, Schultz, Nikolaus, Abou-Alfa, Ghassan K

“…Prior molecular profiling of hepatocellular carcinoma (HCC) has identified actionable findings that may have a role in guiding therapeutic decision-making and…”
Get full text

Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer by Parikh, Aparna R, Van Seventer, Emily E, Siravegna, Giulia, Hartwig, Anna V, Jaimovich, Ariel, He, Yupeng, Kanter, Katie, Fish, Madeleine G, Fosbenner, Kathryn D, Miao, Benchun, Phillips, Susannah, Carmichael, John H, Sharma, Nihaarika, Jarnagin, Joy, Baiev, Islam, Shah, Yojan S, Fetter, Isobel J, Shahzade, Heather A, Allen, Jill N, Blaszkowsky, Lawrence S, Clark, Jeffrey W, Dubois, Jon S, Franses, Joseph W, Giantonio, Bruce J, Goyal, Lipika, Klempner, Samuel J, Nipp, Ryan D, Roeland, Eric J, Ryan, David P, Weekes, Colin D, Wo, Jennifer Y, Hong, Theodore S, Bordeianou, Liliana, Ferrone, Cristina R, Qadan, Motaz, Kunitake, Hiroko, Berger, David, Ricciardi, Rocco, Cusack, James C, Raymond, Victoria M, Talasaz, AmirAli, Boland, Genevieve M, Corcoran, Ryan B

“…Detection of persistent circulating tumor DNA (ctDNA) after curative-intent surgery can identify patients with minimal residual disease (MRD) who will…”
Get full text